PMID- 29519877
OWN - NLM
STAT- MEDLINE
DCOM- 20190920
LR  - 20190920
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 103
IP  - 1
DP  - 2019 Jan
TI  - Type 3 neovascularisation: long-term analysis of visual acuity and optical
      coherence tomography anatomical outcomes.
PG  - 43-48
LID - 10.1136/bjophthalmol-2018-311850 [doi]
AB  - BACKGROUND: To investigate the long-term visual and optical coherence tomography 
      (OCT) anatomical outcomes of type 3 neovascularisation (NV) and to identify any
      baseline predictors of poor outcomes. METHODS: In this retrospective study,
      patients diagnosed with treatment naive type 3 NV were identified and categorised
      into two groups: good or poor vision based on final vision at 1 year. Baseline
      demographic features and visual acuity (VA) and baseline and 1-year spectral
      domain OCT (SD-OCT) anatomical findings were studied and correlated with good
      versus poor visual outcomes. RESULTS: Ten of 25 eyes were classified as having a 
      poor visual outcome (20/50 or worse) at 1 year. Increased age (P=0.049), male
      gender (p=0.041) and worse baseline VA (rhos=0.61, p=0.001) were associated with 
      poor vision at 1 year. Greater foveal atrophy was noted at 1 year in the poor
      visual outcome group (p=0.030). Subretinal hyper-reflective material and
      choroidal thinning were additional features noted more commonly in this group.
      CONCLUSION: Increased age, male gender and lower baseline vision may be important
      baseline predictors of poor visual outcomes in eyes with type 3 NV. The
      development of central outer retinal atrophy and fibrosis, as identified with
      SD-OCT, may limit long-term vision in eyes with type 3 NV.
CI  - (c) Article author(s) (or their employer(s) unless otherwise stated in the text
      of the article) 2019. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Chae, Bora
AU  - Chae B
AD  - Stein Eye Institute, University of California, Los Angeles, California, USA.
FAU - Su, Daniel
AU  - Su D
AD  - Stein Eye Institute, University of California, Los Angeles, California, USA.
FAU - Gal-Or, Orly
AU  - Gal-Or O
AD  - Vitreous, Retina Macula, Consultants of New York, New York City, New York, USA.
AD  - LuEsther T Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital,
      New York, New York, USA.
AD  - Department of Ophthalmology, Rabin Medical Center, Petach Tikva, Israel.
FAU - Freund, K Bailey
AU  - Freund KB
AD  - Vitreous, Retina Macula, Consultants of New York, New York City, New York, USA.
AD  - LuEsther T Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital,
      New York, New York, USA.
AD  - Department of Ophthalmology, New York University School of Medicine, New York,
      New York, USA.
FAU - Sarraf, David
AU  - Sarraf D
AD  - Stein Eye Institute, University of California, Los Angeles, California, USA.
AD  - Department of Ophthalmology, Kaiser Permanente, Woodland Hills, California, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180308
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Retina/*pathology
MH  - *Retinal Neovascularization/drug therapy/pathology/physiopathology
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/*methods
MH  - Vision Disorders/physiopathology
MH  - Visual Acuity/*physiology
OTO - NOTNLM
OT  - *angiogenesis
OT  - *imaging
OT  - *macula
OT  - *neovascularisation
OT  - *vision
COIS- Competing interests: KBF is a consultant for Genentech, Optovue, Optos, Spark
      Therapeutics and Heidelberg Engineering. He receives research support from
      Genentech/Roche. D Sarraf is a consultant for Amgen, Bayer, Novartis, Genentech
      and Optovue and receives research funding from Allergan, Genentech, Heidelberg,
      Optovue and Regeneron. BS, D Su, OG-O: none declared.
EDAT- 2018/03/10 06:00
MHDA- 2019/09/21 06:00
CRDT- 2018/03/10 06:00
PHST- 2018/01/04 00:00 [received]
PHST- 2018/02/14 00:00 [revised]
PHST- 2018/02/17 00:00 [accepted]
PHST- 2018/03/10 06:00 [pubmed]
PHST- 2019/09/21 06:00 [medline]
PHST- 2018/03/10 06:00 [entrez]
AID - bjophthalmol-2018-311850 [pii]
AID - 10.1136/bjophthalmol-2018-311850 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2019 Jan;103(1):43-48. doi: 10.1136/bjophthalmol-2018-311850.
      Epub 2018 Mar 8.